Home
/
LEXICON PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
LEXICON PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that LEXICON PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$14.18M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$28.87M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$1.26M
May 14, 2025
Q3
2025
Sep 30, 2024
$1.75M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$1.65M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$1.13M
May 14, 2025
Q3
2024
Sep 30, 2023
$162.0K
Nov 13, 2024
Q2
2024
Jun 30, 2023
$317.0K
Aug 2, 2024
Q1
2024
Mar 31, 2023
$24.0K
May 2, 2024
Q3
2023
Sep 30, 2022
$39.0K
Nov 8, 2023
Q2
2023
Jun 30, 2022
$35.0K
Aug 4, 2023
Q3
2021
Sep 30, 2021
$23.0K
Nov 9, 2021
Q2
2021
Jun 30, 2021
$234.0K
Aug 6, 2021
Q1
2021
Mar 31, 2021
$27.0K
May 6, 2021
Q3
2021
Sep 30, 2020
$6.63M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$9.16M
Aug 6, 2021
Q1
2020
Jun 30, 2020
$9.16M
Jul 29, 2020
Q1
2021
Mar 31, 2020
$8.00M
May 6, 2021
Q3
2020
Sep 30, 2019
$294.45M
Oct 30, 2020
Q1
2020
Jun 30, 2019
$9.68M
Jul 29, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2025
Mar 31, 2025
$1.26M
May 14, 2025
Q3
2024
Sep 30, 2024
$1.74M
Nov 13, 2024
Q2
2024
Jun 30, 2024
$1.62M
Aug 2, 2024
Q1
2025
Mar 31, 2024
$1.09M
May 14, 2025
Q3
2024
Sep 30, 2023
$148.0K
Nov 13, 2024
Q2
2024
Jun 30, 2023
$291.0K
Aug 2, 2024
Q1
2024
Mar 31, 2023
$0
May 2, 2024
Q3
2023
Sep 30, 2022
$0
Nov 8, 2023
Q2
2023
Jun 30, 2022
$0
Aug 4, 2023
Q3
2021
Sep 30, 2021
$0
Nov 9, 2021
Q2
2021
Jun 30, 2021
$0
Aug 6, 2021
Q1
2021
Mar 31, 2021
$0
May 6, 2021
Q3
2021
Sep 30, 2020
$0
Nov 9, 2021
Q1
2020
Jun 30, 2020
$25.0K
Jul 29, 2020
Q2
2021
Jun 30, 2020
$25.0K
Aug 6, 2021
Q1
2021
Mar 31, 2020
$8.0K
May 6, 2021
Q3
2020
Sep 30, 2019
$285.91M
Oct 30, 2020
Q2
2019
Jun 30, 2019
$860.0K
Aug 1, 2019
Q1
2020
Jun 30, 2019
$860.0K
Jul 29, 2020
Q1
2020
Mar 31, 2019
$2.44M
Apr 27, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.77M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
$3.25M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$3.25M
Aug 6, 2025
Q2
2025
Mar 31, 2025
($25.30M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($25.30M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($25.30M)
May 14, 2025
Q3
2025
Sep 30, 2024
($64.81M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
($53.43M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($53.43M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($48.40M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($48.40M)
May 14, 2025
Q2
2025
Mar 31, 2024
($48.40M)
Aug 6, 2025
Q3
2024
Sep 30, 2023
($50.53M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($44.90M)
Aug 2, 2024
Q3
2024
Jun 30, 2023
($44.90M)
Nov 13, 2024
Q1
2024
Mar 31, 2023
($31.93M)
May 2, 2024
Q2
2024
Mar 31, 2023
($31.93M)
Aug 2, 2024
Q3
2024
Mar 31, 2023
($31.93M)
Nov 13, 2024
Q3
2023
Sep 30, 2022
($23.39M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($24.59M)
Aug 4, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.19M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
$3.74M
Aug 6, 2025
Q1
2025
Mar 31, 2025
($25.68M)
May 14, 2025
Q3
2025
Sep 30, 2024
($63.69M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($55.35M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($45.33M)
May 14, 2025
Q3
2024
Sep 30, 2023
($49.63M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($44.24M)
Aug 2, 2024
Q1
2024
Mar 31, 2023
($31.14M)
May 2, 2024
Q3
2023
Sep 30, 2022
($23.10M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($24.01M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
($23.38M)
May 4, 2023
Q3
2022
Sep 30, 2021
($22.96M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($17.96M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($20.84M)
May 5, 2022
Q3
2021
Sep 30, 2020
$86.68M
Nov 9, 2021
Q1
2020
Jun 30, 2020
($64.58M)
Jul 29, 2020
Q2
2021
Jun 30, 2020
($64.58M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($62.44M)
May 6, 2021
Q3
2020
Sep 30, 2019
$224.68M
Oct 30, 2020